MedCity News4d
Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels
The affirmative regulatory decision is the third for Novartis’s Fabhalta, building up the drug’s pipeline-in-a-product potential. But competition looms from a rival drug taking a similar approach.
pharmaphorum4d
A history of Novartis
Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...
pharmaphorum2d
Novartis decides Sandoz' future – and it's a spin-out
After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...
BioSpace6d
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy. Novartis has secured a ...
Indiatimes3h
Novartis India Share Price
Novartis India Ltd., incorporated in the year 1947, is a Small Cap company (having a market cap of Rs 2,078.97 Crore) operating in Pharmaceuticals sector. Novartis India Ltd. key Products/Revenue ...
Novartis4d
Career Search
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.